曲美他嗪对慢性心力衰竭患者再住院率的影响

Effect of Trimetazidine on the Rehospitalization Rate of Patients with Chronic Heart Failure

目的观察曲美他嗪对慢性心力衰竭患者再住院率及病死率的影响。方法选择2009年6月至2011年2月在东光县医院住院的190例慢性心力衰竭患者,经随机抽样法分为曲美他嗪组100和常规组90例。常规组给予地高辛、β受体阻滞剂、利尿剂、血管紧张素转换酶抑制剂、醛固酮拮抗剂等常规治疗,曲美他嗪组在常规组治疗基础上口服曲美他嗪20 mg,每日3次。观察患者6个月、1年和2年再住院率及病死率。结果两组患者6个月、1年和2年再住院率比较,差异均有统计学意义(P<0.05);病死率比较,差异无统计学意义。结论曲美他嗪治疗慢性心力衰竭安全有效,能降低患者再住院率,但对病死率无影响。

Objective To observe the effect of trimetazidine on the rehospitalization rate and mortality rate of patients with chronic heart failure. Methods A total of 190 patients with chronic heart failure admitted in Donggnang County Hospital from Jun, 2009 to Feb. 2011 were randomly divided into trimetazidine group（ 100 eases） and control group（90 cases）. Patients in the control group received conventional treatment of.digoxin, β-receptor blocking, diuretics, angiotensin converting enzyme inhibitor, and aldosterene antagonists, while patients in trimetazidine group were given an extra 20 mg of trimetazidine orally taken three times a day on the Basis of the conventional treatment. Then the rehospitalization rates and mortality rates of both Stoups were observed 6 months, 1 and 2 years after treatment sepeartely. Results There were statistically sigaificant differences of the rehospitalization rates 6 months, 1 and 2 years after treatment between the two groups（ P 〈0.05 ） ;while there were no statistically significant differences of the mortality rates between the two groups. Canduslon Trimetazidine is safe and effective in treating chronic heart failure. And it can reduce the rehospitalization rate but has no influence on mortality rate.